首页 > 最新文献

Problemy endokrinologii最新文献

英文 中文
[Adaptation of the 12-item medication adherence scale ( the Questionnaire for assessment of adherence to Medication) on a Russian-speaking sample of patients with type 1 and type 2 diabetes mellitus]. [在讲俄语的 1 型和 2 型糖尿病患者样本中改编 12 项用药依从性量表(用药依从性评估问卷)]。
Pub Date : 2024-09-15 DOI: 10.14341/probl13372
V E Epishin, M F Kalashnikova, N V Likhodey, I B Bondareva, A M Kaurova, M V Tulupova, N A Nikolaev, V V Fadeev

Background: Poor adherence to treatment among patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) hinders the effective use of antidiabetic agents and the achievement of optimal glycemic control, reducing their quality of life and outcomes. Assessing adherence to treatment using a questionnaire can help identify and eliminate factors and barriers that negatively affect adherence to medical recommendations and satisfaction with treatment.

Aim: To conduct linguistic and cultural adaptation of the 12-item Medication Adherence Scale (MAS-12) questionnaire and evaluate the psychometric properties of the Russian version of the MAS-12 questionnaire among patients suffering from T1DM and T2DM.

Materials and methods: A survey of 198 patients with T1DM and T2DM was carried out, including self-completion of the MAS-12 questionnaire in Russian. Average age: 47.1±18.62 years, proportion of women - 76%. Average duration of the disease: 13.08±10.05 years. The construct validity of the MAS-12 questionnaire was assessed using confirmatory factor analysis. As an external criterion for assessing convergent validity, the KOP-25 method was used - the Russian Questionnaire for Quantitative Assessment of Treatment Adherence (KOP-25). Reliability of the MAS-12 was assessed using Cronbach's α internal consistency and participant retest after 1 to 4 months.

Results: The factor structure of the MAS-12 questionnaire is reproduced for the first time on a Russian sample of patients with diabetes. Recommended fit indicators for the measurement model (CFI=0.983, RMSEA=0.049, TLI=0.968) were achieved by excluding two items (9 and 12) that did not demonstrate statistically significant contributions to their respective subscales. The internal consistency of the subscales (α ϵ [0.522; 0.857]) and the questionnaire as a whole (α=0.766) was assessed as sufficient. Significant correlations of the adapted methodology and its subscales with the scales of the KOP-25 questionnaire were obtained. The closest connections (r ϵ [0.333; 0.431], p<0.010) are observed with the COP-25 scales related to drug therapy, which indicates good external validity of the adapted methodology.

Conclusion: The Russian version of the MAS-12 questionnaire "Questionnaire for assessing adherence to medication treatment" (PML-10), consisting of 10 questions, has good psychometric properties, is a valid and reliable tool for assessing medication adherence among patients with T1DM and T2DM and can be recommended for use in clinical practice, including for monitoring treatment adherence in Russia.

背景:1 型糖尿病(T1DM)和 2 型糖尿病(T2DM)患者治疗依从性差,阻碍了抗糖尿病药物的有效使用和血糖控制的实现,降低了他们的生活质量和治疗效果。目的:在 T1DM 和 T2DM 患者中对 12 项用药依从性量表(MAS-12)问卷进行语言和文化调整,并评估俄语版 MAS-12 问卷的心理测量特性:对 198 名 T1DM 和 T2DM 患者进行了调查,包括用俄语自填 MAS-12 问卷。平均年龄:47.1±18.62 岁,女性比例为 76%。平均病程13.08±10.05 年。MAS-12 问卷的构建有效性是通过确认性因子分析进行评估的。作为评估收敛效度的外部标准,采用了 KOP-25 方法--俄罗斯治疗依从性定量评估问卷(KOP-25)。MAS-12 的信度采用 Cronbach's α 内部一致性和 1 至 4 个月后的参与者重测进行评估:结果:首次在俄罗斯糖尿病患者样本中再现了 MAS-12 问卷的因子结构。通过排除两个对各自分量表无显著统计学贡献的项目(9 和 12),测量模型达到了推荐的拟合指标(CFI=0.983,RMSEA=0.049,TLI=0.968)。经评估,各分量表(α ϵ [0.522; 0.857])和整个问卷(α=0.766)的内部一致性是充分的。改编方法及其子量表与 KOP-25 问卷的量表之间存在显著的相关性。与药物治疗相关的 COP-25 量表的相关性(r ϵ [0.333; 0.431],p<0.010)最为接近,这表明改编方法具有良好的外部效度:俄文版 MAS-12 问卷 "药物治疗依从性评估问卷"(PML-10)由 10 个问题组成,具有良好的心理测量学特性,是评估 T1DM 和 T2DM 患者药物治疗依从性的有效而可靠的工具,可推荐用于临床实践,包括监测俄罗斯的治疗依从性。
{"title":"[Adaptation of the 12-item medication adherence scale ( the Questionnaire for assessment of adherence to Medication) on a Russian-speaking sample of patients with type 1 and type 2 diabetes mellitus].","authors":"V E Epishin, M F Kalashnikova, N V Likhodey, I B Bondareva, A M Kaurova, M V Tulupova, N A Nikolaev, V V Fadeev","doi":"10.14341/probl13372","DOIUrl":"10.14341/probl13372","url":null,"abstract":"<p><strong>Background: </strong>Poor adherence to treatment among patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) hinders the effective use of antidiabetic agents and the achievement of optimal glycemic control, reducing their quality of life and outcomes. Assessing adherence to treatment using a questionnaire can help identify and eliminate factors and barriers that negatively affect adherence to medical recommendations and satisfaction with treatment.</p><p><strong>Aim: </strong>To conduct linguistic and cultural adaptation of the 12-item Medication Adherence Scale (MAS-12) questionnaire and evaluate the psychometric properties of the Russian version of the MAS-12 questionnaire among patients suffering from T1DM and T2DM.</p><p><strong>Materials and methods: </strong>A survey of 198 patients with T1DM and T2DM was carried out, including self-completion of the MAS-12 questionnaire in Russian. Average age: 47.1±18.62 years, proportion of women - 76%. Average duration of the disease: 13.08±10.05 years. The construct validity of the MAS-12 questionnaire was assessed using confirmatory factor analysis. As an external criterion for assessing convergent validity, the KOP-25 method was used - the Russian Questionnaire for Quantitative Assessment of Treatment Adherence (KOP-25). Reliability of the MAS-12 was assessed using Cronbach's α internal consistency and participant retest after 1 to 4 months.</p><p><strong>Results: </strong>The factor structure of the MAS-12 questionnaire is reproduced for the first time on a Russian sample of patients with diabetes. Recommended fit indicators for the measurement model (CFI=0.983, RMSEA=0.049, TLI=0.968) were achieved by excluding two items (9 and 12) that did not demonstrate statistically significant contributions to their respective subscales. The internal consistency of the subscales (α ϵ [0.522; 0.857]) and the questionnaire as a whole (α=0.766) was assessed as sufficient. Significant correlations of the adapted methodology and its subscales with the scales of the KOP-25 questionnaire were obtained. The closest connections (r ϵ [0.333; 0.431], p&lt;0.010) are observed with the COP-25 scales related to drug therapy, which indicates good external validity of the adapted methodology.</p><p><strong>Conclusion: </strong>The Russian version of the MAS-12 questionnaire \"Questionnaire for assessing adherence to medication treatment\" (PML-10), consisting of 10 questions, has good psychometric properties, is a valid and reliable tool for assessing medication adherence among patients with T1DM and T2DM and can be recommended for use in clinical practice, including for monitoring treatment adherence in Russia.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"70 4","pages":"32-43"},"PeriodicalIF":0.0,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical case of plurihormonal pituitary adenoma (STH/ACTH/TSH/FSH/LH-secreting), diagnostic pitfalls]. [多激素垂体腺瘤(分泌 STH/ACTH/TSH/FSH/LH)的临床病例,诊断陷阱]。
Pub Date : 2024-09-15 DOI: 10.14341/probl13349
D N Kostyleva, P M Khandaeva, A M Lapshina, E G Przhialkovskaya, Zh E Belaya, А Yu Grigoriev, G A Mel'nichenko

According to numerous studies, the most common pituitary tumors are prolactinomas, reaching 60% of all clinically significant adenomas, the next in order are non-functional pituitary adenomas, somatotropinomas, corticotropinomas and thyrotropinomas. Plurigormonal tumors occur in less than 1% of all pituitary adenomas. The most common form of mixed secretion adenoma in this patient population, derived from the Pit-1 cell line, produces various combinations of hormones: growth hormone (GH), prolactin (PRL), thyroid-stimulating hormone (TSH). This article presents a patient with a plurihormonal two-component pituitary macroadenoma with a rare and exceptional combination of secreted hormones - GH / adrenocorticotropic hormone (ACTH) / TSH / follicle-stimulating hormone (FSH) / luteinizing hormone (LH) with minimal nonspecific clinical manifestations such as diabetes mellitus and poorly controlled arterial hypertension.

根据大量研究,最常见的垂体瘤是催乳素瘤,占所有有临床意义腺瘤的 60%,其次依次是无功能垂体腺瘤、促瘤、促皮质素瘤和促甲状腺素瘤。在所有垂体腺瘤中,多激素瘤的发生率不到 1%。这类患者中最常见的混合分泌腺瘤来自 Pit-1 细胞系,可产生多种激素组合:生长激素(GH)、催乳素(PRL)和促甲状腺激素(TSH)。本文介绍了一名患有多激素双组分垂体大腺瘤的患者,其分泌激素的组合罕见而特殊--生长激素(GH)/促肾上腺皮质激素(ACTH)/促甲状腺激素(TSH)/卵泡刺激素(FSH)/促黄体生成素(LH),并伴有极少的非特异性临床表现,如糖尿病和控制不佳的动脉高血压。
{"title":"[Clinical case of plurihormonal pituitary adenoma (STH/ACTH/TSH/FSH/LH-secreting), diagnostic pitfalls].","authors":"D N Kostyleva, P M Khandaeva, A M Lapshina, E G Przhialkovskaya, Zh E Belaya, А Yu Grigoriev, G A Mel'nichenko","doi":"10.14341/probl13349","DOIUrl":"10.14341/probl13349","url":null,"abstract":"<p><p>According to numerous studies, the most common pituitary tumors are prolactinomas, reaching 60% of all clinically significant adenomas, the next in order are non-functional pituitary adenomas, somatotropinomas, corticotropinomas and thyrotropinomas. Plurigormonal tumors occur in less than 1% of all pituitary adenomas. The most common form of mixed secretion adenoma in this patient population, derived from the Pit-1 cell line, produces various combinations of hormones: growth hormone (GH), prolactin (PRL), thyroid-stimulating hormone (TSH). This article presents a patient with a plurihormonal two-component pituitary macroadenoma with a rare and exceptional combination of secreted hormones - GH / adrenocorticotropic hormone (ACTH) / TSH / follicle-stimulating hormone (FSH) / luteinizing hormone (LH) with minimal nonspecific clinical manifestations such as diabetes mellitus and poorly controlled arterial hypertension.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"70 4","pages":"24-31"},"PeriodicalIF":0.0,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Multiplex analysis of post-Covid cardiorenal complications in patients with type 1 and type 2 diabetes mellitus according to the mobile diagnostic and treatment center (Diamobil)]. [根据流动诊疗中心(Diamobil)对1型和2型糖尿病患者科维德后心肾并发症的多重分析]。
Pub Date : 2024-09-15 DOI: 10.14341/probl13426
O К Vikulova, A V Zheleznyakova, A A Serkov, M A Isakov, G R Vagapova, F V Valeeva, N P Trubicina, O G Melnikova, V K Aleksandrova, N B Smirnova, D N Egorova, E V Artemova, K V Sorokina, M V Shestakova, N G Mokrysheva, I I Dedov

Background: Patients with diabetes mellitus (DM) are at risk for a higher incidence and severity of COVID-19, as well as its adverse outcomes, including post-Covid syndrome.

Aim: to assess the incidence of cardiorenal complications in patients with type 1 and type 2 diabetes (T1DM/T2DM) who have had COVID-19, and to analyze the structure and severity of disorders according to examination data at the Diamobil mobile medical diagnostic and treatment center.

Materials and methods: a cohort of T1DM and T2DM patients examined in Diamobil (n=318), with a confirmed anamnesis of COVID-19 (n=236). The time interval between COVID-19 and the visit to Diamobil was 8.7/8.2 months for T1DM/T2DM. The parameters of the last visit before COVID-19 recorded in the Federal Register of Diabetes (FRD) were used as initial data.

Results: Clinical characteristics of patients with T1DM/T2DM: age - 49.2/64.5 years, duration of DM - 22/11 years, proportion of women - 64/73%, respectively. After analysis the data from visits before and after COVID-19 there weren't statistically significant differences in HbA1c levels for both types of DM (before 9.0/8.3%; after 8.4/8.2%, respectively), there was the intensification of glucose lowering therapy (the proportion of patients with T2DM on 2 and 3 component therapy increased by 4.3% and 1.6%, the proportion of patients on insulin therapy by 16%). After COVID-19, there was a statistically significant decrease in glomerular filtration rate (GFR) in T1DM from 88.1 to 62 ml/min/1.73 m2; with T2DM from 74.7 to 54.1 ml/min/1.73 m2. When assessing acute diabetic complications, there was an increase in the frequency of coma in T1DM by 1.5 times, severe hypoglycemia in T1DM by 3 times, and in T2DM by 1.7 times. Analysis of the frequency of cardiorenal complications before and after COVID-19 showed a total increase of 8.5% in T1DM, by 13.2% in T2DM, of which myocardial infarction, ischemic heart disease, and CHF increased in T1DM in the range from 1.5 to 5 times, with T2DM by 1.3 times, the frequency of CKD with T1DM by 1.5 times, with T2DM by 5.6 times.

Conclusion: There was a decline of kidney filtration function (decrease in GFR) and an increase in the frequency of cardiovascular complications in both types of diabetes in post-Covid period while patients achieved a stable HbA1c levels by intensifying therapy during the COVID-19 infection. This fact reflects combined damage to the kidney and cardiovascular system as a part of the post-Covid syndrome and determines a key set of measures for the development of preventive strategies.

背景:糖尿病(DM)患者COVID-19的发生率和严重程度以及其不良后果(包括后Covid综合征)均较高。目的:评估1型和2型糖尿病(T1DM/T2DM)患者发生COVID-19后心肾并发症的发生率,并根据Diamobil移动医疗诊断和治疗中心的检查数据,分析疾病的结构和严重程度。材料和方法:在Diamobil接受检查的T1DM和T2DM患者队列(n=318),其中有确诊COVID-19的病史(n=236)。T1DM/T2DM患者从COVID-19到Diamobil就诊的时间间隔为8.7/8.2个月。联邦糖尿病登记册(FRD)中记录的 COVID-19 前最后一次就诊的参数被用作初始数据:T1DM/T2DM患者的临床特征:年龄分别为49.2岁/64.5岁,糖尿病病程分别为22年/11年,女性比例分别为64%/73%。对 COVID-19 前后的就诊数据进行分析后发现,两种类型的糖尿病患者的 HbA1c 水平在统计学上没有显著差异(之前分别为 9.0/8.3%;之后分别为 8.4/8.2%),但降糖治疗得到了加强(接受 2 种和 3 种成分治疗的 T2DM 患者比例分别增加了 4.3% 和 1.6%,接受胰岛素治疗的患者比例增加了 16%)。COVID-19 治疗后,T1DM 患者的肾小球滤过率(GFR)从 88.1 毫升/分钟/1.73 平方米降至 62 毫升/分钟/1.73 平方米,T2DM 患者的肾小球滤过率从 74.7 毫升/分钟/1.73 平方米降至 54.1 毫升/分钟/1.73 平方米,差异有统计学意义。在评估糖尿病急性并发症时,T1DM 发生昏迷的频率增加了 1.5 倍,T1DM 发生严重低血糖的频率增加了 3 倍,T2DM 发生严重低血糖的频率增加了 1.7 倍。COVID-19前后心肾并发症发生率分析显示,T1DM共增加8.5%,T2DM增加13.2%,其中心肌梗死、缺血性心脏病和CHF在T1DM中增加1.5至5倍,在T2DM中增加1.3倍,CKD在T1DM中增加1.5倍,在T2DM中增加5.6倍:结论:在感染 COVID-19 期间,患者通过加强治疗达到稳定的 HbA1c 水平,但在感染 COVID-19 后,肾脏滤过功能下降(GFR 减少),两种类型糖尿病的心血管并发症发生率增加。这一事实反映了作为后科维德综合征一部分的肾脏和心血管系统的综合损害,并为制定预防战略确定了一套关键措施。
{"title":"[Multiplex analysis of post-Covid cardiorenal complications in patients with type 1 and type 2 diabetes mellitus according to the mobile diagnostic and treatment center (Diamobil)].","authors":"O К Vikulova, A V Zheleznyakova, A A Serkov, M A Isakov, G R Vagapova, F V Valeeva, N P Trubicina, O G Melnikova, V K Aleksandrova, N B Smirnova, D N Egorova, E V Artemova, K V Sorokina, M V Shestakova, N G Mokrysheva, I I Dedov","doi":"10.14341/probl13426","DOIUrl":"10.14341/probl13426","url":null,"abstract":"<p><strong>Background: </strong>Patients with diabetes mellitus (DM) are at risk for a higher incidence and severity of COVID-19, as well as its adverse outcomes, including post-Covid syndrome.</p><p><strong>Aim: </strong>to assess the incidence of cardiorenal complications in patients with type 1 and type 2 diabetes (T1DM/T2DM) who have had COVID-19, and to analyze the structure and severity of disorders according to examination data at the Diamobil mobile medical diagnostic and treatment center.</p><p><strong>Materials and methods: </strong>a cohort of T1DM and T2DM patients examined in Diamobil (n=318), with a confirmed anamnesis of COVID-19 (n=236). The time interval between COVID-19 and the visit to Diamobil was 8.7/8.2 months for T1DM/T2DM. The parameters of the last visit before COVID-19 recorded in the Federal Register of Diabetes (FRD) were used as initial data.</p><p><strong>Results: </strong>Clinical characteristics of patients with T1DM/T2DM: age - 49.2/64.5 years, duration of DM - 22/11 years, proportion of women - 64/73%, respectively. After analysis the data from visits before and after COVID-19 there weren't statistically significant differences in HbA1c levels for both types of DM (before 9.0/8.3%; after 8.4/8.2%, respectively), there was the intensification of glucose lowering therapy (the proportion of patients with T2DM on 2 and 3 component therapy increased by 4.3% and 1.6%, the proportion of patients on insulin therapy by 16%). After COVID-19, there was a statistically significant decrease in glomerular filtration rate (GFR) in T1DM from 88.1 to 62 ml/min/1.73 m2; with T2DM from 74.7 to 54.1 ml/min/1.73 m2. When assessing acute diabetic complications, there was an increase in the frequency of coma in T1DM by 1.5 times, severe hypoglycemia in T1DM by 3 times, and in T2DM by 1.7 times. Analysis of the frequency of cardiorenal complications before and after COVID-19 showed a total increase of 8.5% in T1DM, by 13.2% in T2DM, of which myocardial infarction, ischemic heart disease, and CHF increased in T1DM in the range from 1.5 to 5 times, with T2DM by 1.3 times, the frequency of CKD with T1DM by 1.5 times, with T2DM by 5.6 times.</p><p><strong>Conclusion: </strong>There was a decline of kidney filtration function (decrease in GFR) and an increase in the frequency of cardiovascular complications in both types of diabetes in post-Covid period while patients achieved a stable HbA1c levels by intensifying therapy during the COVID-19 infection. This fact reflects combined damage to the kidney and cardiovascular system as a part of the post-Covid syndrome and determines a key set of measures for the development of preventive strategies.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"70 4","pages":"65-74"},"PeriodicalIF":0.0,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Hypophisitis in pregnant women with persistent diabetes insipidus in the outcome]. [妊娠合并顽固性尿崩症孕妇的尿道下裂]。
Pub Date : 2024-09-15 DOI: 10.14341/probl13384
L K Dzeranova, E A Pigarova, S Yu Vorotnikova, A A Voznesenskaya

Autoimmune/lymphocytic hypophysitis is one of the rare causes of central diabetes insipidus in adults and is most common among women in the second or third trimester of pregnancy. Numerous studies have shown that lymphocytic hypophysitis is characterized by a very variable clinical signs with the development of neurological symptoms, visual disturbances and hypopituitarism with partial or complete loss of pituitary function, as well as a number of features in magnetic resonance imaging (MRI). Isolated lymphocytic indibuloneurohypophysitis occurs in fewer cases and involves the posterior lobe and stalk of the pituitary gland with a clinical presentation of diabetes insipidus. The above clinical case describes the development of hypophysitis in a pregnant woman with a predominant lesion of the posterior pituitary gland and an outcome in diabetes insipidus, which persists 6 years after pregnancy and childbirth. In the article some aspects of the differential diagnosis of diabetes insipidus in pregnant women, as well as instrumental diagnosis and treatment approaches of hypophysitis are discussed.

自身免疫/淋巴细胞性腺功能减退症是导致成人中枢性糖尿病的罕见病因之一,在妊娠第二或第三季度的妇女中最为常见。大量研究表明,淋巴细胞性肾上腺皮质功能减退症的临床表现非常多变,会出现神经系统症状、视力障碍和垂体功能减退,垂体功能部分或完全丧失,磁共振成像(MRI)也有一些特征。孤立性淋巴细胞性垂体后叶和垂体柄炎发生率较低,临床表现为尿崩症。上述临床病例描述了一名孕妇患上以垂体后叶病变为主的垂体功能减退症,并在妊娠和分娩后 6 年仍患上糖尿病。文章讨论了孕妇糖尿病性脂质减少症的鉴别诊断、仪器诊断和治疗方法。
{"title":"[Hypophisitis in pregnant women with persistent diabetes insipidus in the outcome].","authors":"L K Dzeranova, E A Pigarova, S Yu Vorotnikova, A A Voznesenskaya","doi":"10.14341/probl13384","DOIUrl":"10.14341/probl13384","url":null,"abstract":"<p><p>Autoimmune/lymphocytic hypophysitis is one of the rare causes of central diabetes insipidus in adults and is most common among women in the second or third trimester of pregnancy. Numerous studies have shown that lymphocytic hypophysitis is characterized by a very variable clinical signs with the development of neurological symptoms, visual disturbances and hypopituitarism with partial or complete loss of pituitary function, as well as a number of features in magnetic resonance imaging (MRI). Isolated lymphocytic indibuloneurohypophysitis occurs in fewer cases and involves the posterior lobe and stalk of the pituitary gland with a clinical presentation of diabetes insipidus. The above clinical case describes the development of hypophysitis in a pregnant woman with a predominant lesion of the posterior pituitary gland and an outcome in diabetes insipidus, which persists 6 years after pregnancy and childbirth. In the article some aspects of the differential diagnosis of diabetes insipidus in pregnant women, as well as instrumental diagnosis and treatment approaches of hypophysitis are discussed.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"70 4","pages":"15-23"},"PeriodicalIF":0.0,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Etiopathogenetic features of bone metabolism in patients with diabetes mellitus and Charcot foot]. [糖尿病和夏科足患者骨代谢的病因特征]。
Pub Date : 2024-09-15 DOI: 10.14341/probl13362
M V Yaroslavceva, O N Bondarenko, Ya A El-Taravi, S T Magerramova, E A Pigarova, I N Ulyanova, G R Galstyan

Diabetic neuropathy is one of the most common diabetes mellitus complications associated with mediocalcinosis of the lower extremities, a significant decrease in feet bone mineral density, and a high incidence of cardiovascular disease. In most cases, calcium-phosphorus metabolism changes occur in patients with diabetic neuroarthropathy, or Charcot foot, when we can observe feet local osteoporosis, which in 90% of cases associated with a vessel's calcification of the lower extremities in the majority of diabetes population. A large number of studies presented literature have demonstrated that patients with Charcot foot can have accelerated bone metabolism and increased bone resorption. Patients with Charcot foot often have crucial abnormalities in the calcium-phosphorus parameters, bone metabolism, and levels of vitamin D and its metabolites. In addition, the duration of diabetes mellitus, the degree of its compensation widely affects the development of its micro- and macrovascular complications, which could also accelerate the development of mineral and bone disorders in these types of patients. Multifactorial pathogenesis of these disorders complicates the management of patients with a long and complicated course of diabetes mellitus. This review discusses the peculiarities of vitamin D metabolism, the importance of timely diagnosis in phosphorus-calcium disorders, and the specifics of therapy in these patients. Special attention is paid to the timely diagnosis of the Charcot's foots acute stage based on the bone marrow edema by MRI evaluation and the possibility of reducing the immobilization period.

糖尿病神经病变是最常见的糖尿病并发症之一,与下肢中钙化、足部骨矿密度明显降低和心血管疾病的高发病率有关。在大多数情况下,钙磷代谢变化发生在糖尿病神经性关节病或夏科足患者身上,此时我们可以观察到足部局部骨质疏松症,在 90% 的病例中,大多数糖尿病患者的下肢与血管钙化有关。大量研究文献表明,Charcot 足患者的骨代谢加速,骨吸收增加。夏科脚患者通常在钙磷参数、骨代谢、维生素 D 及其代谢物水平方面存在严重异常。此外,糖尿病病程的长短、糖尿病的代偿程度会广泛影响其微血管和大血管并发症的发展,这也会加速这类患者矿物质和骨骼紊乱的发展。这些疾病的多因素致病机理使得对病程长、病情复杂的糖尿病患者的治疗变得更加复杂。本综述讨论了维生素 D 代谢的特殊性、及时诊断磷钙紊乱的重要性以及这些患者的具体治疗方法。其中特别关注通过磁共振成像评估骨髓水肿,及时诊断沙氏足急性期,以及缩短固定期的可能性。
{"title":"[Etiopathogenetic features of bone metabolism in patients with diabetes mellitus and Charcot foot].","authors":"M V Yaroslavceva, O N Bondarenko, Ya A El-Taravi, S T Magerramova, E A Pigarova, I N Ulyanova, G R Galstyan","doi":"10.14341/probl13362","DOIUrl":"10.14341/probl13362","url":null,"abstract":"<p><p>Diabetic neuropathy is one of the most common diabetes mellitus complications associated with mediocalcinosis of the lower extremities, a significant decrease in feet bone mineral density, and a high incidence of cardiovascular disease. In most cases, calcium-phosphorus metabolism changes occur in patients with diabetic neuroarthropathy, or Charcot foot, when we can observe feet local osteoporosis, which in 90% of cases associated with a vessel's calcification of the lower extremities in the majority of diabetes population. A large number of studies presented literature have demonstrated that patients with Charcot foot can have accelerated bone metabolism and increased bone resorption. Patients with Charcot foot often have crucial abnormalities in the calcium-phosphorus parameters, bone metabolism, and levels of vitamin D and its metabolites. In addition, the duration of diabetes mellitus, the degree of its compensation widely affects the development of its micro- and macrovascular complications, which could also accelerate the development of mineral and bone disorders in these types of patients. Multifactorial pathogenesis of these disorders complicates the management of patients with a long and complicated course of diabetes mellitus. This review discusses the peculiarities of vitamin D metabolism, the importance of timely diagnosis in phosphorus-calcium disorders, and the specifics of therapy in these patients. Special attention is paid to the timely diagnosis of the Charcot's foots acute stage based on the bone marrow edema by MRI evaluation and the possibility of reducing the immobilization period.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"70 4","pages":"57-64"},"PeriodicalIF":0.0,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551796/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Highly selective sodium-glucose co-transporter type 2 inhibitor empagliflozin as means of brain protection in conditions of chronic brain dyscirculation]. [高选择性钠-葡萄糖协同转运体 2 型抑制剂 Empagliflozin 作为慢性脑循环障碍情况下的脑保护手段]。
Pub Date : 2024-09-15 DOI: 10.14341/probl13336
A V Simanenkova, O S Fuks, N V Timkina, D A Sufieva, O V Kirik, D E Korzhevskii, T D Vlasov, T L Karonova
<p><strong>Background: </strong>Chronic brain dyscirculation is one of the frequent type 2 diabetes mellitus (DM) complications and leads to patients' disability. Sodium-glucose co-transporter type 2 inhibitors (SGLT-2i) have been proven to have advantages for cardiovascular system, but their effect on the central nervous system (CNS) has not been studied enough.</p><p><strong>Aim: </strong>To study empagliflozin effect on CNS damage functional and laboratory parameters in patients with type 2 DM and, under experimental conditions, to investigate the mechanisms of the drug neurotropic effect.</p><p><strong>Materials and methods: </strong>The clinical part of the study included patients with type 2 DM on metformin monotherapy (n=39). Patients with a target glycated hemoglobin level formed the "MET" group (n=19), in patients with a non-target glycated hemoglobin level empagliflozin was co-administered for the following 6 months (the "MET+EMPA" group, n=20). Healthy volunteers comprised the control group (n=16). The cognitive status and neuron-specific enolase (NSE) and neurofilament light chains (NLC) concentration were studied. DM was modeled in rats, thereafter the rats were treated with empagliflozin for 8 weeks. Microglia activation was assessed using anti-Iba-1 antibodies and morphological changes in neurons when stained by the Nissl method.</p><p><strong>Results: </strong>Both in the "MET+EMPA" and the "MET" groups cognitive deficits were observed, according to the Montreal Cognitive Assessment (MOCA) (24.0 (23.0; 27.0) and 25.0 (21.0; 27.0) points) and the Mini-Mental State Examination (MMSE) (23.75 (23.0; 27.0) and 25.0 (21.0; 27.0) points). Empagliflozin therapy led to the cognitive status normalization after 6 months (26.5 (24.0; 27.0) points according to the MOCA scale and 27.5 (24.0; 28.0) points according to the MMSE). Initially, all patients had a significant increase of NSE (3.60 (2.66; 3.76) ng/ml in the "MET" group, 3.22 (2.94; 3.54) ng/ml in the "MET+EMPA» group, 2.72 (2.13; 2.72) ng/ml in the «Control» group) and NLC (4.50 (3.31; 5.56) ng/ml in the «MET» group, 5, 25 (3.75; 6.25) ng/ml in the «MET+EMPA» group comparing with 3.50 (2.25; 3.50) ng/ml in the «Control» group). Empagliflozin therapy led to a significant decrease in NLC already after 3 months (3.80 (3.25; 3.87) ng/ml), without significant influence on the NSE level. In the experiment, DM was characterized by an increased number of activated microgliocytes and destructured neurons and a decreased number of neurons with a normal structure. Empagliflozin therapy was accompanied by a decrease in the number of immunopositive microgliocytes in the CA1 zone of the hippocampus and an increase in the number of structured neurons.</p><p><strong>Conclusion: </strong>Type 2 diabetes mellitus is characterized by functional and biochemical changes in the central nervous system even under satisfactory glycemic control. Therapy with empagliflozin has a neuroprotective effect, manifeste
背景:慢性脑循环障碍是2型糖尿病(DM)常见并发症之一,并导致患者残疾。目的:研究恩格列净(empagliflozin)对2型DM患者中枢神经系统损伤的功能和实验室指标的影响,并在实验条件下探讨该药物神经刺激作用的机制:研究的临床部分包括接受二甲双胍单药治疗的2型糖尿病患者(39人)。达到目标糖化血红蛋白水平的患者组成 "MET "组(n=19),非目标糖化血红蛋白水平的患者在随后的6个月中联合使用empagliflozin("MET+EMPA "组,n=20)。对照组由健康志愿者组成(n=16)。对认知状态、神经元特异性烯醇化酶(NSE)和神经丝蛋白轻链(NLC)浓度进行了研究。对大鼠进行DM建模,然后用empagliflozin治疗8周。使用抗Iba-1抗体评估小胶质细胞的活化情况,使用Nissl方法染色评估神经元的形态学变化:根据蒙特利尔认知评估(MOCA)(24.0(23.0;27.0)分和25.0(21.0;27.0)分)和迷你精神状态检查(MMSE)(23.75(23.0;27.0)分和25.0(21.0;27.0)分),"MET+EMPA "组和 "MET "组均出现认知障碍。Empagliflozin 治疗 6 个月后认知状态恢复正常(MOCA 量表显示 26.5 (24.0; 27.0) 分,MMSE 显示 27.5 (24.0; 28.0) 分)。最初,所有患者的 NSE 都显著增加("MET "组为 3.60 (2.66; 3.76) ng/ml,"MET+EMPA "组为 3.22 (2.94; 3.54) ng/ml,"MET+EMPA "组为 2.72 (2.13; 2.72) ng/ml)。72)纳克/毫升)和NLC("MET "组为4.50(3.31;5.56)纳克/毫升,"MET+EMPA "组为5.25(3.75;6.25)纳克/毫升,而 "对照 "组为3.50(2.25;3.50)纳克/毫升)。Empagliflozin 治疗 3 个月后,NLC 已显著下降(3.80 (3.25; 3.87) ng/ml),但对 NSE 水平没有显著影响。在实验中,DM 的特征是活化的小胶质细胞和结构破坏的神经元数量增加,而结构正常的神经元数量减少。恩格列净治疗后,海马CA1区免疫阳性小胶质细胞数量减少,结构正常的神经元数量增加:2型糖尿病即使在血糖控制良好的情况下,中枢神经系统的功能和生化变化也是其特征。使用恩格列净治疗具有神经保护作用,表现为认知状态的改善和NLC水平的下降。Empagliflozin 可减少神经元损伤和小胶质细胞的异常激活。
{"title":"[Highly selective sodium-glucose co-transporter type 2 inhibitor empagliflozin as means of brain protection in conditions of chronic brain dyscirculation].","authors":"A V Simanenkova, O S Fuks, N V Timkina, D A Sufieva, O V Kirik, D E Korzhevskii, T D Vlasov, T L Karonova","doi":"10.14341/probl13336","DOIUrl":"10.14341/probl13336","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Chronic brain dyscirculation is one of the frequent type 2 diabetes mellitus (DM) complications and leads to patients' disability. Sodium-glucose co-transporter type 2 inhibitors (SGLT-2i) have been proven to have advantages for cardiovascular system, but their effect on the central nervous system (CNS) has not been studied enough.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Aim: &lt;/strong&gt;To study empagliflozin effect on CNS damage functional and laboratory parameters in patients with type 2 DM and, under experimental conditions, to investigate the mechanisms of the drug neurotropic effect.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;The clinical part of the study included patients with type 2 DM on metformin monotherapy (n=39). Patients with a target glycated hemoglobin level formed the \"MET\" group (n=19), in patients with a non-target glycated hemoglobin level empagliflozin was co-administered for the following 6 months (the \"MET+EMPA\" group, n=20). Healthy volunteers comprised the control group (n=16). The cognitive status and neuron-specific enolase (NSE) and neurofilament light chains (NLC) concentration were studied. DM was modeled in rats, thereafter the rats were treated with empagliflozin for 8 weeks. Microglia activation was assessed using anti-Iba-1 antibodies and morphological changes in neurons when stained by the Nissl method.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Both in the \"MET+EMPA\" and the \"MET\" groups cognitive deficits were observed, according to the Montreal Cognitive Assessment (MOCA) (24.0 (23.0; 27.0) and 25.0 (21.0; 27.0) points) and the Mini-Mental State Examination (MMSE) (23.75 (23.0; 27.0) and 25.0 (21.0; 27.0) points). Empagliflozin therapy led to the cognitive status normalization after 6 months (26.5 (24.0; 27.0) points according to the MOCA scale and 27.5 (24.0; 28.0) points according to the MMSE). Initially, all patients had a significant increase of NSE (3.60 (2.66; 3.76) ng/ml in the \"MET\" group, 3.22 (2.94; 3.54) ng/ml in the \"MET+EMPA» group, 2.72 (2.13; 2.72) ng/ml in the «Control» group) and NLC (4.50 (3.31; 5.56) ng/ml in the «MET» group, 5, 25 (3.75; 6.25) ng/ml in the «MET+EMPA» group comparing with 3.50 (2.25; 3.50) ng/ml in the «Control» group). Empagliflozin therapy led to a significant decrease in NLC already after 3 months (3.80 (3.25; 3.87) ng/ml), without significant influence on the NSE level. In the experiment, DM was characterized by an increased number of activated microgliocytes and destructured neurons and a decreased number of neurons with a normal structure. Empagliflozin therapy was accompanied by a decrease in the number of immunopositive microgliocytes in the CA1 zone of the hippocampus and an increase in the number of structured neurons.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Type 2 diabetes mellitus is characterized by functional and biochemical changes in the central nervous system even under satisfactory glycemic control. Therapy with empagliflozin has a neuroprotective effect, manifeste","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"70 4","pages":"44-56"},"PeriodicalIF":0.0,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The functional role and properties of transcortin in the human body]. [转皮质素在人体内的功能作用和特性]。
Pub Date : 2024-08-01 DOI: 10.14341/probl13482
A Chevais, M M Gadzhimuradova, D G Beltsevich, A N Romanova, K Sh Begova, H V Bagirova, A K Ebzeeva, G A Melnichenko

Steroid hormones take an active part in a whole complex of physiological processes that are fundamental for the normal development and functioning of the human body. In the bloodstream steroid hormones are bind with specific transport proteins, in particular with transcortin. The matter of changes in hormone-protein complex in various conditions were actively studied in the second half of the twentieth century, but currently this issue has been taken a back seat by the development of high-precision diagnostic methods of steroid hormones determining. This literature review presents accumulated data on the physicochemical properties of transcortin, genetic factors affecting its synthesis and secretion. Published data on its physiological significance in the human body are analyzed in detail within the framework of not only the "free hormone" hypothesis, but also the reservoir hypothesis. Research results have shown that the synthesis of transcortin has been detected in some extrahepatic tissues, including the adrenal glands, however, its role is unknown.

类固醇激素在整个复杂的生理过程中起着积极的作用,这些生理过程是人体正常发育和功能的基础。在血液中,类固醇激素与特定的转运蛋白结合,特别是与转质蛋白结合。20世纪下半叶,人们积极研究各种条件下激素蛋白复合物的变化问题,但目前由于类固醇激素测定的高精度诊断方法的发展,这一问题已被置于次要地位。本文综述了有关转肾上腺素的理化性质、影响其合成和分泌的遗传因素等方面的研究进展。在“游离激素”假说和“储存库假说”的框架下,详细分析了已发表的关于其在人体生理意义的数据。研究结果表明,在包括肾上腺在内的一些肝外组织中已检测到transcortin的合成,但其作用尚不清楚。
{"title":"[The functional role and properties of transcortin in the human body].","authors":"A Chevais, M M Gadzhimuradova, D G Beltsevich, A N Romanova, K Sh Begova, H V Bagirova, A K Ebzeeva, G A Melnichenko","doi":"10.14341/probl13482","DOIUrl":"10.14341/probl13482","url":null,"abstract":"<p><p>Steroid hormones take an active part in a whole complex of physiological processes that are fundamental for the normal development and functioning of the human body. In the bloodstream steroid hormones are bind with specific transport proteins, in particular with transcortin. The matter of changes in hormone-protein complex in various conditions were actively studied in the second half of the twentieth century, but currently this issue has been taken a back seat by the development of high-precision diagnostic methods of steroid hormones determining. This literature review presents accumulated data on the physicochemical properties of transcortin, genetic factors affecting its synthesis and secretion. Published data on its physiological significance in the human body are analyzed in detail within the framework of not only the \"free hormone\" hypothesis, but also the reservoir hypothesis. Research results have shown that the synthesis of transcortin has been detected in some extrahepatic tissues, including the adrenal glands, however, its role is unknown.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"70 6","pages":"27-34"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143049394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Immunological status in patients with amenorrhea (literature review)]. 【闭经患者的免疫学状况(文献综述)】。
Pub Date : 2024-06-04 DOI: 10.14341/probl13456
Y S Absatarova, Y S Evseeva, E N Andreeva, Z T Zuraeva, E V Sheremetyeva, O R Grigoryan, R K Mikheev

Amenorrhea is a common symptom of a whole range of nosologies among women of reproductive age, which can accompany any endocrinopathy in the stage of decompensation. In all the diversity of various links in the pathogenesis of reproductive disorders, the problem of immunopathology remains a little aside, however, the significance of these disorders is underestimated. This publication provides an overview of immune system abnormalities in a women with amenorrhea. As is known, in polycystic ovary syndrome (PCOS) and premature ovarian insufficiency (POI), one of the clinical manifestations is amenorrhea. On the one hand, these nosologies differ significantly from each other in etiology, pathogenesis and approaches to therapy, and on the other hand, they have a common similarity, manifested by immunological disorders. The article provides information about the immune status of patients with PCOS and POI. Works devoted to various disorders in the immune system, pathologies of humoral and cellular immunity, which in the future may serve as the key to the development of new and non-standard methods of treating such socially significant diseases, are analyzed. Literature search was carried out in national (eLibrary, CyberLeninka.ru) and international (PubMed, Cochrane Library) databases in Russian and English. The choice of sources was prioritized for the period from 2018 to 2024.

闭经是育龄妇女的一种常见症状,在失代偿期可伴有任何内分泌病。在生殖疾病发病机制的各个环节的多样性中,免疫病理问题仍然是一个小问题,然而,这些疾病的重要性被低估了。本出版物提供了免疫系统异常的妇女闭经的概述。众所周知,在多囊卵巢综合征(PCOS)和卵巢功能不全(POI)中,闭经是临床表现之一。这些病种一方面在病因、发病机制和治疗方法上存在显著差异,另一方面又有共同的相似之处,表现为免疫功能紊乱。本文提供了有关PCOS和POI患者免疫状况的信息。致力于各种免疫系统紊乱,体液和细胞免疫病理的工作,这些工作在未来可能成为治疗这些社会重大疾病的新方法和非标准方法发展的关键,进行了分析。文献检索在国内(Library, CyberLeninka.ru)和国际(PubMed, Cochrane Library)数据库中进行了俄文和英文检索。在2018年至2024年期间,优先选择来源。
{"title":"[Immunological status in patients with amenorrhea (literature review)].","authors":"Y S Absatarova, Y S Evseeva, E N Andreeva, Z T Zuraeva, E V Sheremetyeva, O R Grigoryan, R K Mikheev","doi":"10.14341/probl13456","DOIUrl":"10.14341/probl13456","url":null,"abstract":"<p><p>Amenorrhea is a common symptom of a whole range of nosologies among women of reproductive age, which can accompany any endocrinopathy in the stage of decompensation. In all the diversity of various links in the pathogenesis of reproductive disorders, the problem of immunopathology remains a little aside, however, the significance of these disorders is underestimated. This publication provides an overview of immune system abnormalities in a women with amenorrhea. As is known, in polycystic ovary syndrome (PCOS) and premature ovarian insufficiency (POI), one of the clinical manifestations is amenorrhea. On the one hand, these nosologies differ significantly from each other in etiology, pathogenesis and approaches to therapy, and on the other hand, they have a common similarity, manifested by immunological disorders. The article provides information about the immune status of patients with PCOS and POI. Works devoted to various disorders in the immune system, pathologies of humoral and cellular immunity, which in the future may serve as the key to the development of new and non-standard methods of treating such socially significant diseases, are analyzed. Literature search was carried out in national (eLibrary, CyberLeninka.ru) and international (PubMed, Cochrane Library) databases in Russian and English. The choice of sources was prioritized for the period from 2018 to 2024.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"70 6","pages":"118-126"},"PeriodicalIF":0.0,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143049379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The history of the institute of higher and additional professional education of the Endocrinology Reserch Centre]. [内分泌学研究中心高等和额外专业教育学院的历史]。
Pub Date : 2024-06-04 DOI: 10.14341/probl13470
S V Sumina, E A Pigarova, L K Dzeranova, A G Kuzmin

The Endocrinology Reserch Centre is proud not only of its achievements in the area of personalized approach to the examination and treatment of patients in accordance with the principles of evidence-based medicine, the use of modern diagnostic and treatment technologies, but also of its rich history of training scientific and medical personnel. For many years the Center has been attracting the best and most talented graduates of higher medical institutions, becoming the "alma mater" for young doctors - endocrinologists, pediatric endocrinologists and nutritionists. Specialists, graduates of NMRC, make a significant contribution to the development of medicine, conducting research, creating innovative methods of treatment and helping patients not only in our country, but also abroad. However, the State Research Center of the Russian Federation FGBU «NMRC Endocrinology» is famous not only for its high-quality and comprehensive training, but also for its experienced, dedicated teaching staff, giving students unique opportunities for professional growth. The purpose of this article is to reflect the most important milestones in the development of education at NMIC Endocrinology, which began its formation more than a century ago, during the most difficult period of transition for our country.

内分泌学研究中心引以为豪的不仅是它在根据循证医学原则对病人进行个性化检查和治疗、使用现代诊断和治疗技术方面取得的成就,还有它在培养科学和医学人才方面的丰富历史。多年来,该中心一直吸引着高等医疗机构最优秀、最有才华的毕业生,成为年轻医生--内分泌科医生、儿科内分泌科医生和营养科医生--的 "母校"。国家医学研究中心的毕业生、专家们为医学发展做出了重大贡献,他们不仅在国内,还在国外开展研究、创造创新的治疗方法并帮助病人。然而,俄罗斯联邦国立格大 "NMRC 内分泌学 "研究中心不仅以其高质量和全面的培训而闻名,还以其经验丰富、兢兢业业的教师队伍而闻名,为学生提供了独特的专业成长机会。本文旨在反映 "国家医学中心内分泌学 "教育发展中最重要的里程碑事件。"国家医学中心内分泌学 "成立于一个多世纪前,当时正值我国最艰难的转型时期。
{"title":"[The history of the institute of higher and additional professional education of the Endocrinology Reserch Centre].","authors":"S V Sumina, E A Pigarova, L K Dzeranova, A G Kuzmin","doi":"10.14341/probl13470","DOIUrl":"10.14341/probl13470","url":null,"abstract":"<p><p>The Endocrinology Reserch Centre is proud not only of its achievements in the area of personalized approach to the examination and treatment of patients in accordance with the principles of evidence-based medicine, the use of modern diagnostic and treatment technologies, but also of its rich history of training scientific and medical personnel. For many years the Center has been attracting the best and most talented graduates of higher medical institutions, becoming the \"alma mater\" for young doctors - endocrinologists, pediatric endocrinologists and nutritionists. Specialists, graduates of NMRC, make a significant contribution to the development of medicine, conducting research, creating innovative methods of treatment and helping patients not only in our country, but also abroad. However, the State Research Center of the Russian Federation FGBU «NMRC Endocrinology» is famous not only for its high-quality and comprehensive training, but also for its experienced, dedicated teaching staff, giving students unique opportunities for professional growth. The purpose of this article is to reflect the most important milestones in the development of education at NMIC Endocrinology, which began its formation more than a century ago, during the most difficult period of transition for our country.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"70 3","pages":"4-8"},"PeriodicalIF":0.0,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141790813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[First experience using an aromatase inhibitor in combination with growth hormone to improve growth prognosis in a 14-year-old boy with growth hormone deficiency after treatment of craniopharyngioma. A case-report]. [首次使用芳香酶抑制剂联合生长激素改善14岁男孩颅咽管瘤治疗后生长激素缺乏的生长预后。病例报告)。
Pub Date : 2024-05-21 DOI: 10.14341/probl13446
N A Mazerkina, S K Gorelyshev, A N Savateev, N A Strebkova, A L Kalinin

This article describes the first experience of successful use of growth hormone (GH) in combination with an aromatase inhibitor (AI), in a 14-year-old boy. At the age of 7, he presented with headaches, nausea and vomiting, and MRI revealed a craniopharyngioma (CP). An Ommaya system was implanted, and radiation therapy was performed. As a result of treatment, GH deficiency and secondary hypothyroidism developed. At age 9 years, signs of puberty appeared. Growth rate remained satisfactory until the age of 14 years. At the age of 14 growth rate slowed down, which was the reason for appointment. Upon examination, the bone age was 16 years and the projected final height without therapy was 162 cm. Given the poor growth prognosis, IA anastrozole in combination with GH was prescribed. During two years of therapy the growth gain amounted to 12.5 cm. This observation demonstrates that normal growth rates in patients with CP do not indicate preserved somatotropic function of the pituitary gland. With preserved sexual function, early or premature puberty may be observed. In such cases, IA can be prescribed in addition to GH - these are medications that inhibit the closure of growth. GH therapy in combination with IA is highly effective and safe in patients with GH deficiency after treatment of KF during puberty and allows to achieve good growth parameters.

本文描述了第一次成功使用生长激素(GH)与芳香酶抑制剂(AI)的经验,在一个14岁的男孩。7岁时出现头痛、恶心和呕吐,MRI显示颅咽管瘤(CP)。植入了Ommaya系统,并进行了放射治疗。作为治疗的结果,生长激素缺乏和继发性甲状腺功能减退。9岁时,青春期的迹象出现了。直到14岁,生长速度仍令人满意。在14岁时,生长速度减慢,这是预约的原因。经检查,骨龄为16岁,未治疗的预计最终身高为162厘米。鉴于生长预后不良,开具了IA阿那曲唑联合生长激素。在两年的治疗期间,生长增重达12.5厘米。这一观察结果表明,CP患者的正常生长速率并不表明垂体的促生长功能得到保留。性功能保留的情况下,可以观察到过早或过早的青春期。在这种情况下,除了生长激素外,还可以开IA——这些药物可以抑制生长闭合。生长激素治疗联合IA对青春期KF治疗后的生长激素缺乏症患者是非常有效和安全的,并且可以获得良好的生长参数。
{"title":"[First experience using an aromatase inhibitor in combination with growth hormone to improve growth prognosis in a 14-year-old boy with growth hormone deficiency after treatment of craniopharyngioma. A case-report].","authors":"N A Mazerkina, S K Gorelyshev, A N Savateev, N A Strebkova, A L Kalinin","doi":"10.14341/probl13446","DOIUrl":"10.14341/probl13446","url":null,"abstract":"<p><p>This article describes the first experience of successful use of growth hormone (GH) in combination with an aromatase inhibitor (AI), in a 14-year-old boy. At the age of 7, he presented with headaches, nausea and vomiting, and MRI revealed a craniopharyngioma (CP). An Ommaya system was implanted, and radiation therapy was performed. As a result of treatment, GH deficiency and secondary hypothyroidism developed. At age 9 years, signs of puberty appeared. Growth rate remained satisfactory until the age of 14 years. At the age of 14 growth rate slowed down, which was the reason for appointment. Upon examination, the bone age was 16 years and the projected final height without therapy was 162 cm. Given the poor growth prognosis, IA anastrozole in combination with GH was prescribed. During two years of therapy the growth gain amounted to 12.5 cm. This observation demonstrates that normal growth rates in patients with CP do not indicate preserved somatotropic function of the pituitary gland. With preserved sexual function, early or premature puberty may be observed. In such cases, IA can be prescribed in addition to GH - these are medications that inhibit the closure of growth. GH therapy in combination with IA is highly effective and safe in patients with GH deficiency after treatment of KF during puberty and allows to achieve good growth parameters.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"71 1","pages":"66-71"},"PeriodicalIF":0.0,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11931461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143635060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Problemy endokrinologii
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1